This medical condition has either been superseded or has become inactive
Specific Conditions |
|
Indication for Ig Use |
|
Level of Evidence | Insufficient data (Category 4a) |
Description and Diagnostic Criteria | OMA is an immune-mediated monophasic or multiphasic disorder consisting of opsoclonus (conjugate chaotic eye movements), cerebellar ataxia, and arrhythmic myoclonus affecting the trunk, the head and the extremities. OMA may be either paraneoplastic or idiopathic, presumably para-infectious (e.g. post-viral). In children, OMA complicates about 2–3% of neuroblastomas. In adults, it may occur in association with several cancers, most commonly small-cell lung cancer and breast cancer. |
Justification for Evidence Category | The Asia–Pacific IVIg Advisory Board (Kornberg 2004) consensus statement summarises several case reports suggesting that intravenous immunoglobulin (IVIg) is useful in idiopathic OMA and childhood paraneoplastic OMA associated with neuroblastoma. |
Diagnosis Requirements |
A diagnosis must be made by a Neurologist. |
Qualifying Criteria for Ig Therapy |
Child with OMA.
Child less than 18 years
Long-term maintenance therapy of OMA in association with other tumour therapies.
AND
|
Review Criteria for Assessing the Effectiveness of Ig Use |
Child with OMA.
IVIg should be used for six months before determining whether the patient has responded. If there has been no benefit after six months treatment, IVIg therapy should be abandoned.
Review by a Neurologist is required after the first six months of treatment. For stable patients on maintenance treatment, review by a Neurologist is required at least annually. Documentation of clinical effectiveness is necessary for continuation of IVIg therapy. On review of the initial authorisation period Clinical effectiveness of Ig therapy may be demonstrated by:
On review of a continuing authorisation period Clinical effectiveness of Ig therapy may be demonstrated by:
Long-term maintenance therapy of OMA in association with other tumour therapies.
IVIg should be used for six months before determining whether the patient has responded. If there has been no benefit after six months of treatment, IVIg therapy should be abandoned.
Review by a Neurologist is required after the first six months of treatment. For stable patients on maintenance treatment, review by a Neurologist is required at least annually. Documentation of clinical effectiveness is necessary for continuation of IVIg therapy. On review of the initial authorisation period Clinical effectiveness of Ig therapy may be demonstrated by:
On review of a continuing authorisation period Clinical effectiveness of Ig therapy may be demonstrated by:
|
Dose |
Child with OMA.
Aim for the minimum dose to maintain optimal functional status.
The aim should be to use the lowest dose possible that achieves the appropriate clinical outcome for each patient. Refer to the current product information sheet for further information. Long-term maintenance therapy of OMA in association with other tumour therapies.
Aim for the minimum dose to maintain optimal functional status.
The aim should be to use the lowest dose possible that achieves the appropriate clinical outcome for each patient. Refer to the current product information sheet for further information. |
Bibliography |
---|
Glatz, K, Meinck, HM & Wildemann, B 2003, ‘Para-infectious opsoclonus-myoclonus syndrome: high dose intravenous immunoglobulins are effective’, Journal of Neurology, Neurosurgery and Psychiatry, vol. 74, no. 2, pp. 279–80. Kornberg, AJ 2004, Bringing consensus to the use of IVIg in neurology. Expert consensus statements on the use of IVIg in neurology, 1st edn, for the Asia–Pacific IVIg Advisory Board, Melbourne, pp. 80–82. National Institute of Neurological Disorders 2006, ‘NINDS opsoclonus myoclonus information page’, January. Available from: http://www.ninds.nih.gov/disorders/opsoclonus_myoclonus/opsoclonus_myoclonus.htm [cited 7 Dec 2007] |